Scott Floyd

In addition to being a Koch Institute Clinical Investigator, Scott Floyd, M.D., Ph.D. is a brain tumor specialist and radiation oncologist at Beth Israel Deaconess Medical Center. He has first-hand knowledge of the devastating impact of brain tumors and side effects of many current cancer therapies. His research at the Koch Institute is centered on finding ways to make these treatments more effective, and less harmful, for patients.

Dr. Floyd’s research career began at Vanderbilt University in Nashville, TN where his undergraduate studies were concentrated in molecular biology and music.  There, he completed his undergraduate research thesis in protein crystallography and x-ray fiber diffraction with Prof. Gerald Stubbs. He then entered the Yale University MD/PhD program, and performed his graduate work in the Interdepartmental Neuroscience Program.  His PhD thesis work was completed with Prof. Pietro De Camilli where he investigated the connections between autoimmune neurological syndromes and cancer.  After completing his MD and PhD degrees, Dr. Floyd did his internal medicine internship at the Hospital of St. Raphael in New Haven and then entered the Harvard Radiation Oncology Program, a combined residency training at Massachusetts General Hospital, Brigham and Women’s Hospital, Children’s Hospital, Beth Israel Deaconess Medical Center, Boston Medical Center and the Dana Farber Cancer Institute. During this training, he first came to the Koch Institute as an American Board of Radiology Holman Pathway Research Fellow working in the laboratory of Prof. Michael Yaffe on modifiers of the DNA damage response.  Dr. Floyd took a staff position at the Beth Israel Deaconess Medical Center in 2007, where he specializes in the treatment of both primary and metastatic central nervous system tumors in the Beth Israel Deaconess Brain Tumor Center and Department of Radiation Oncology. He will now join the Koch Institute as a Clinical Investigator and continue his research to improve brain tumor treatment by studying the DNA damage effects of chromatin modifiers.